Zobrazeno 1 - 4
of 4
pro vyhledávání: '"James T. Coates"'
Autor:
Leif W. Ellisen, Aditya Bardia, Gad Getz, Dejan Juric, Laxmi Parida, Steven J. Isakoff, James R. Stone, Avinash Kambadakone, Charlotte S. Walmsley, Elyssa Denault, Chaya Levovitz, Filippo Utro, Kahn Rhrissorrakrai, Raquel A. Jacobs, Kara Slowik, Brian P. Danysh, Daniel McLoughlin, Elizabeth E. Martin, Nayana Thimmiah, Ignaty Leshchiner, Sheng Sun, James T. Coates
Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e216b65b6323310fb4109676f0f444f4
https://doi.org/10.1158/2159-8290.c.6549032.v1
https://doi.org/10.1158/2159-8290.c.6549032.v1
Autor:
Leif W. Ellisen, Aditya Bardia, Gad Getz, Dejan Juric, Laxmi Parida, Steven J. Isakoff, James R. Stone, Avinash Kambadakone, Charlotte S. Walmsley, Elyssa Denault, Chaya Levovitz, Filippo Utro, Kahn Rhrissorrakrai, Raquel A. Jacobs, Kara Slowik, Brian P. Danysh, Daniel McLoughlin, Elizabeth E. Martin, Nayana Thimmiah, Ignaty Leshchiner, Sheng Sun, James T. Coates
Figure S1, radiographic assessment of key lesions of patient MGH-18; Figure S2, supplementary genomic analysis for patient MGH-18; Figure S3, supporting data for mechanism of TROP2 T256R; Figure S4, TROP2 immunohistochemistry for metastatic lesions o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb8df6c82c7a9007f2bd80489e828ed
https://doi.org/10.1158/2159-8290.22539245.v1
https://doi.org/10.1158/2159-8290.22539245.v1
Autor:
James T Coates, Christiaan de Koning
Publikováno v:
Journal of the Royal Society of Medicine. 115(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b988b412f619be3d2139ac4451b41df
https://pubmed.ncbi.nlm.nih.gov/36321679
https://pubmed.ncbi.nlm.nih.gov/36321679
Autor:
Aditya Bardia, James T. Coates, Laura Spring, Sheng Sun, Dejan Juric, Nayana Thimmiah, Andrzej Niemierko, Phoebe Ryan, Ann Partridge, Jeffrey Peppercorn, Heather Parsons, Seth Wander, Kelsey Pierce, Victoria Attaya, Donna Fitzgerald, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Bev Moy, Sara Tolaney, Leif Ellisen
Publikováno v:
Cancer Research. 82:2638-2638
Background: Sacituzumab Govitecan (SG), the first antibody-drug conjugate approved for metastatic TNBC (mTNBC), is comprised of SN-38 (active metabolite of irinotecan), a topoisomerase I (TOP1) inhibitor, coupled via a hydrolyzable linker to monoclon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b60ae80d4c9fa6ffa289395bce0b42b
https://doi.org/10.1158/1538-7445.am2022-2638
https://doi.org/10.1158/1538-7445.am2022-2638